Summary
Signal counts
Assets tracked: 2
Watchlist assets: 0
Registry stop assets: 0
Sponsor overview
US Oncology Research
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT00303108 | https://clinicaltrials.gov/study/NCT00493649
Assets
Linked programs
- Pegylated liposomal doxorubicin: Low Signal (1/5)
- Taxotere: Low Signal (1/5)